melagatran has been researched along with Aging in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eriksson, UG; Grind, M; Svensson, M; Wåhlander, K; Wollbratt, M; Wolzt, M | 1 |
| Andersson, M; Bylock, A; Eriksson, UG; Johnsson, G; Nakanishi, T; Nyström, P; Wernevik, LC | 1 |
2 trial(s) available for melagatran and Aging
| Article | Year |
|---|---|
Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.
Topics: Administration, Oral; Adult; Aged; Aging; Area Under Curve; Atrial Fibrillation; Azetidines; Benzylamines; Female; Glycine; Humans; Infusions, Intravenous; Male; Middle Aged; Thrombin | 2003 |
Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran.
Topics: Administration, Oral; Adult; Aged; Aging; Anticoagulants; Area Under Curve; Asian People; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Humans; Male; Metabolic Clearance Rate; Prodrugs; Single-Blind Method; Thrombin; White People | 2006 |